Cyclophilin A Human
Cyclophilin-A Human Recombinant
Cat. No.
BT2717
Source
Escherichia Coli.
Synonyms
Peptidylprolyl isomerase A, CYPA, CYPH, MGC12404, MGC23397, MGC117158, PPIase A, Rotamase A, PPIA, Peptidyl-prolyl cis-trans isomerase A, EC 5.2.1.8, Cyclophilin A, Cyclosporin A-binding protein.
Appearance
Sterile filtered colorless solution.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
Cyclophilin-A Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 185 amino acids (1-165 a.a.) and having a molecular mass of 20 kDa.
PPIase-A is purified by proprietary chromatographic techniques.
PPIase-A is purified by proprietary chromatographic techniques.
Product Specs
Introduction
Peptidyl-prolyl cis-trans isomerases (PPIases) like Cyclophilin-A play a crucial role in protein folding by catalyzing the cis-trans isomerization of proline imidic peptide bonds. This protein is known to bind cyclosporin A, potentially contributing to its immunosuppressive effects. Additionally, Cyclophilin-A interacts with several HIV proteins, including p55 gag, Vpr, and capsid protein, and is essential for the formation of infectious HIV virions. The human genome contains multiple pseudogenes of Cyclophilin-A located on different chromosomes.
Description
Recombinant Human Cyclophilin-A, expressed in E. coli, is a non-glycosylated polypeptide with a 20 amino acid His tag at its N-terminus. This protein consists of 185 amino acids (including the His tag; the native protein sequence comprises residues 1-165) and has a molecular weight of 20 kDa. Purification is achieved through proprietary chromatographic techniques, resulting in a single polypeptide chain.
Physical Appearance
A clear, colorless solution free from particulate matter.
Formulation
The protein is supplied as a 1 mg/ml solution in a buffer consisting of 20mM Tris-HCl (pH 8.0), 20mM NaCl, 0.5mM DTT, and 10% glycerol.
Stability
For short-term storage (up to 4 weeks), the product can be stored at 4°C. For extended storage, freeze the solution at -20°C. The addition of a carrier protein like HSA or BSA (0.1%) is recommended for long-term storage. To maintain product integrity, avoid repeated freeze-thaw cycles.
Biological Activity
The enzyme exhibits a specific activity exceeding 650 nmol/min/mg. This is determined by measuring the enzyme's ability to cleave 1 nanomole of the substrate suc-AAFP-PNA per minute at 37°C in a Tris-HCl buffer (pH 8.0) using chymotrypsin.
Purity
SDS-PAGE analysis indicates a purity level greater than 95%.
Synonyms
Peptidylprolyl isomerase A, CYPA, CYPH, MGC12404, MGC23397, MGC117158, PPIase A, Rotamase A, PPIA, Peptidyl-prolyl cis-trans isomerase A, EC 5.2.1.8, Cyclophilin A, Cyclosporin A-binding protein.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MVNPTVFFDI AVDGEPLGRV SFELFADKVP KTAENFRALSTGEKGFGYKG SCFHRIIPGF MCQGGDFTRH NGTGGKSIYG EKFEDENFIL KHTGPGILSMANAGPNTNGS QFFICTAKTE WLDGKHVVFG KVKEGMNIVE AMERFGSRNG KTSKKITIADCGQLE.
Product Science Overview
Functions and Roles
CypA has a broad spectrum of functions and exists in both intracellular and secreted forms . Intracellularly, it is present in nearly all cells, either in the cytosol or nucleus, and functions as a chaperone and housekeeping protein . It also acts as a ligand for cyclosporine A (CsA), an immunosuppressive drug .
Secreted CypA, on the other hand, plays several roles:
- Proinflammatory Factor: It acts as a chemoattractant and immune regulator .
- Antitumor Immunity: It has been identified as a factor in antitumor immunity .
- Clinical Applications: Experimental data suggest potential applications of recombinant human CypA (rhCypA) in cancer immunotherapy, stimulation of tissue regeneration, treatment of brain pathologies, and as a supportive treatment for CsA-based therapies .
Pharmacokinetics
Recent studies have analyzed the pharmacokinetics of rhCypA in mouse models . These studies involved isotope-labeling rhCypA with 125I and injecting it intraperitoneally (i.p.) or subcutaneously (s/c) into mice . The results showed:
- Rapid and Even Tissue-Organ Distribution: rhCypA exhibited rapid and even distribution across tissues and organs .
- Highest Tropism to Kidneys: The highest accumulation was observed in the kidneys, the primary excretory organ .
- Crossing the Blood-Brain Barrier: For the first time, rhCypA was shown to cross the blood-brain barrier and accumulate in the brain .
Historical Context
CypA was originally isolated from bovine thymocytes and identified as the cytosolic receptor for the immunosuppressive cyclic undecapeptide cyclosporin A . The formation of a CypA-CsA complex impairs the transcription of genes related to the immune response and prevents the proliferation of T cells .
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
